BioSpace News Archive

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800

Walgreens Boots Alliance, Inc. announced the early results and upsizing of the previously announced cash tender offer to purchase up to an amended Maximum Tender Amount of the outstanding senior notes identified in the table below, in the order of priority and subject to the Tender Caps shown in the table.

THC Therapeutics, Inc. (OTC PINK:THCT), a forward-thinking, publicly-traded technology company, whose mission statement is, “Better Health through the Science of Nature,” is pleased to announce that the company has arrived at a final design for the consumer market model of the dHydronator®

This World Meningitis Day (April 24th), Meningitis Foundation Canada (MFC) is raising awareness of this ‘indiscriminate killer disease’ and calling on all Canadian provincial and territorial policymakers to act to #DefeatMeningitis by 2030.

Jolly Good Inc. (“Jolly Good”) and Teijin Pharma Ltd. (“Teijin Pharma”) have signed a business partnership agreement to develop VR digital therapeutics (“VR DTx”) for Major Depressive Disorder (MDD). Together, they will promote the development of VR DTx for depression, aiming for PMDA regulatory approval.

Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team.

FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the “Company” or “FSD Pharma”) announces the filing of its Management Information Circular (the “Circular”) and an accompanying letter to shareholders related to the Annual & Special Meeting scheduled for May 14, 2021, copies of which are available under the Company’s SEDAR profile

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the first quarter 2021, after the market closes on Wednesday, May 5, 2021.

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment Data presented today in a late-breaking oral presentation at AAD VMX 2021 Management to host an investor call today at 12:00 p.m. EDT

Recommendation based on positive results from the Phase 3 CheckMate -743 trial, in which Opdivo plus Yervoy demonstrated significantly superior overall survival vs. standard-of-care chemotherapy